Revesta Cholecalciferol Capsules Rx Only

Manufacturer
Sterling Knight Pharmaceuticals,LLC
Effective date
2019-12-16
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
9
Source
full-release
Hydrated at
2026-05-31 20:30:42

Label at a glance#

ProductRevesta
Active ingredientCHOLECALCIFEROL, FOLIC ACID
Label structure11 sections

Indications and uses

Revesta is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D deficiency or are in need of Vitamin D supplementation and other nutritional supplementation.

Dosage and administration

Take one capsule daily or as directed by a physician.

Storage and handling

Store at controlled room temperature 15°-30°C (59°F-86°F). Keep in cool dry place. Call your doctor about side effects. You may report side effects to FDA at 1-800-FDA-1088 . KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Revesta is an orally administered prescription Vitamin for the dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D supplementation due to Vitamin D deficiency and other nutritional supplementation.

Revesta should be administered under the supervision of a licensed medical practitioner.

Vitamin D3 (cholecalciferol) is a white, crystalline powder, very soluble in water, with the following structural formula:

ciffformulaciffformula

Each capsule contains:
Folic Acid: 1mg, Vitamin D3 (Cholecalciferol): 5750IU

Each capsule contains the following inactive ingredients: soybean oil, gelatin (bovine), yellow wax, glycerin, deionized water, lecithin, titanium dioxide, FD&C Blue #1.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Revesta is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D deficiency or are in need of Vitamin D supplementation and other nutritional supplementation.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules.

There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Revesta is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breast-feeding. Consult your doctor about the risks and benefits.

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

This medication is generally well tolerated. Notify your doctor if you experience: nausea, loss of appetite, vomiting, stomach cramps, dry mouth, increased thirst, increased urination, muscle or bone pain,headache, weakness, weight loss, dizziness. If you notice other effects not listed above, contact your doctor or pharmacist.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Take one capsule daily or as directed by a physician.

HOW SUPPLIED

HOW SUPPLIED SECTION

Revesta capsules are supplied as blue capsules imprinted in white ink “330”, dispensed in HDPE plastic bottles of 30ct.

STORAGE AND HANDLING SECTION

Store at controlled room temperature 15°-30°C (59°F-86°F). Keep in cool dry place.

Call your doctor about side effects. You may report side effects to FDA at 1-800-FDA-1088.

KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

OTHER SAFETY INFORMATION

Reserved for Professional Recommendation

All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.

PACKAGE LABEL. PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Rx Only
Reserved for Professional Recommendation
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.

Manufactured for:Sterling Knight Pharmaceuticals, LLC
Ripley, MS 38663
Rev. 1114-1

revestarevesta

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1601102cholecalciferol 5750 UNT / folic acid 1 MG Oral CapsulePSN9
1601102cholecalciferol 5750 UNT / folic acid 1 MG Oral CapsuleSCD9
1601102cholecalciferol 5750 UNT / folate 1 MG Oral CapsuleSY9
1601102vitamin D3 5750 UNT / folic acid 1 MG Oral CapsuleSY9

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CHOLECALCIFEROL Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
baf7f49c-75b6-496b-a00e-8e766a8e4f03Product name120210127
91c62db0-0295-c81c-d10a-0856c259edd6Product name220200428
d32bc2b8-0bb7-2216-87aa-24639646e202Product name320190619
ebc62596-fc97-4d03-9483-7ba095d25db7Product name120151210
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
60c52429-fcef-eb54-2387-43bc9e4f296bProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
69336-330-302021-01-29C16284748780-1ba0f9c33-1680-a910-e053-dadaa90a0b85Revesta Cholecalciferol Capsules Rx Only

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
69336-330-30Revesta30 in 1 BOTTLE, PLASTICCAPSULE309

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
69336-330REVESTA CAPSULE [STERLING KNIGHT PHARMACEUTICALS,LLC]9Legacy NDC, 1 package rows20191217_e5567a73-bf94-4bad-ade6-ddef18c8af04.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
69336-330-30EA - Each69336-330fcca2333-1f03-4e44-8e35-0391a25d894912016-11-08

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
69336-33069336-330-30

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 10 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
99d751a9-5482-0c33-e053-2a95a90a1d82e5567a73-bf94-4bad-ade6-ddef18c8af042019-12-16Warnings, Adverse reactionsExact identifier
spl id: 99d751a9-5482-0c33-e053-2a95a90a1d82
spl set id: e5567a73-bf94-4bad-ade6-ddef18c8af04

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.